Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5925354A · kind A · utility
35Cited by
10References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 1996 |
| Grant date | Jul 20, 1999 |
| Priority date | — |
| Expiry date | Oct 28, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is a vaccine against Actinobacillus pleuropneumoniae (APP) comprising genetically defined biochemically attenuated mutant of APP that requires riboflavin and is attenuated in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.